U.S. Approves First Daily Pill for Weight Loss

U.S. health regulators have approved the first daily pill for weight management, offering a new, more convenient option for millions of Americans. The U.S. Food and Drug Administration (FDA) has cleared an oral version of the blockbuster drug Wegovy, ending its era as an injection-only treatment [32691][32774][32809].

The newly approved pill contains the same active ingredient, semaglutide, as the popular weekly injection [32691][32872]. It belongs to a class of medicines known as GLP-1 (glucagon-like peptide-1) receptor agonists, which work by mimicking a natural hormone that regulates appetite and blood sugar [32691][32872]. The high-dose pill is approved for long-term weight management in adults with obesity or who are overweight with at least one related health condition, such as high blood pressure [32691][32872].

This approval is based on strong clinical trial data. In key studies, participants taking the daily semaglutide pill lost an average of 15% to 16.6% of their body weight over 68 weeks [32744][32774][33049]. The FDA’s decision is expected to significantly widen access to the medication, as many patients prefer a pill over an injection [32744][32872].

"The approval could make the treatment more accessible. Some patients prefer pills over injections," one report noted [32691]. The drugmaker, Novo Nordisk, has stated the pill is now shipping to major U.S. pharmacies, including retailers like CVS and Costco [42244].

While offering a new format, the treatment guidelines remain the same. Experts and the FDA emphasize that the medication is intended for use alongside a reduced-calorie diet and increased physical activity for best results [32691][32744]. Common side effects are similar to the injection and are primarily gastrointestinal, including nausea and diarrhea [32691][32872].

The approval solidifies Novo Nordisk's position in the competitive market for weight-loss drugs and gives the company a first-mover advantage over rivals developing similar oral medications [32787][32809]. In a move to capture market share, the company has announced an aggressive introductory price of $149 per month for the lowest doses of the new pill [42183].